introduction diabetic chronic kidney disease ckd common cause end-stage kidney disease korea almost end-stage kidney disease eskd case caused diabetic ckd diabetic ckd poor prognosis showing increased mortality rapid progression eskd compared non-diabetic ckd etiology diabetic ckd multifactorial including genetic environmental factor high blood glucose level blood pressure prolonged activation renin–angiotensin–aldosterone system obesity risk factor associated progression diabetic ckd however variability remains unaccounted conventional risk factor instance many patient diabetic ckd poor glycemic control develop renal complication discrepancy attributed genetic epigenetic factor genetic code explain fraction diabetic ckd development epigenetic programming remodeling post-translational modification advanced glycation end product regarded recently possible physiological mechanism epigenetic change including dna methylation histone modification mirna regulation play major role pathogenesis diabetic ckd dna methylation directly impact human genome function serf critical regulatory function epigenetic change thought important determining predisposition diabetic ckd addition elevated glucose level reactive oxygen specie hypoxia inflammation cytokine drug nutrition physical activity also modify epigenetic profile several study investigated dna methylation profile diabetic ckd however study case–control study dna methylation profile renal function decline diabetic ckd scarce korean cohort study outcome patient chronic kidney disease know-ckd largest ckd cohort korea establish clinical course risk factor adverse outcome ckd article published clinical marker anemia mineral bone disease quality life serum biomarkers fgf23 adiponectin hepcidin ckd korean population using know-ckd cohort however epigenetic biomarkers decline estimated glomerular filtration rate egfr assessed know-ckd cohort study aimed identify epigenetic biomarkers associated rapid decline egfr observed know-ckd subject using blood sample diabetic ckd material method ethic inclusion statement acquired written informed consent blood sample participant study approved institutional review board seoul national university hospital h-1805-168-948 also confirmed method carried accordance relevant guideline regulation data source study population know-ckd cohort used perform ewas diabetic ckd progression know-ckd study prospective multicenter cohort involving participant specific cause chronic kidney disease ckd grouped glomerulonephritis diabetic nephropathy hypertensive nephropathy htn polycystic kidney disease pkd unclassified supplementary fig subgroup defined pathologic diagnosis available otherwise clinical diagnosis identified presence glomerular hematuria albuminuria without underlying systemic disease diagnosed based albuminuria individual type diabetes mellitus diabetic retinopathy htn determined hypertension history absence systemic illness associated renal damage pkd diagnosed using unified ultrasound criterion causative disease classified 'unclassified know-ckd cohort described detail elsewhere population divided non-progression progression based egfr slope 2.6 ml/min/1.73 calculated median egfr slope know-ckd cohort addition threshold egfr slope htn 2.1 ml/min/1.73 2.6 ml/min/1.73 previous study study follow-up genome-wide association study gwas know-ckd group participant know-ckd individual passed quality control gwas supplementary fig estimated appropriate number participant included ewas based power calculation statistical power estimated minimum maximum participant assuming 1:1 ratio progression non-progression 780,000 total cpg site targeted cpg site minimum detection m-value|= 0.01 limma method fdr threshold 0.05 simulation supplementary fig based power calculation attempted perform ewas participant matched sex age baseline egfr progression non-progression group however participant failed final epigenomic sample process therefore participant progression non-progression included ewas also performed pyrosequencing analysis validation total individual know-ckd excluding ewas matched age sex baseline egfr passed pyrosequencing supplementary fig supplementary table selected addition individual progression non-progression diagnosed biopsy seoul national university hospital snuh human biobank included pyrosequencing analysis supplementary fig finally pyrosequencing analysis performed based total participant supplementary fig outcome measurement egfr calculated using four-variable chronic kidney disease epidemiology collaboration equation egfr slope know-ckd cohort calculated based linear mixed model random intercept using mixed procedure software institute inc. cary north carolina egfr slope estimated using creatinine value measured every time point initiation cohort month initiation cohort least one follow-up since every 1–7 year participant egfr measured least three time included lmm fitted follow-up time dependent variable egfr independent variable fixed effect effect time egfr fixed effect represents average change egfr time participant random effect participant-specific intercept slope association time egfr random intercept represents variation among participant baseline level egfr random slope term time capture variation among participant rate change egfr time therefore lmm fitted allowing participant baseline level egfr rate change egfr time egfr time time egfr egfr slope i-th subject j-th observation time point time follow-up time i-th subject j-th observation time point fixed effect intercept fixed effect intercept egfr slope random effect intercept i-th subject random effect slope i-th subject error term residual hypertension defined systolic blood pressure mmhg diastolic blood pressure mmhg past medical history diabetes mellitus defined serum hemoglobin a1c 6.5 fasting blood glucose mg/dl past medical history ckd progression defined egfr slope 2.6 ml/min/1.73 epigenome-wide dna methylation profiling genomic dna extracted leukocyte peripheral blood sample comparison methylation profile among primary outcome ckd progression vs. non-progression performed using illumina infinium methylationepic platform microarray-based dna methylation level individual profiled using illumina infinium methylationepic beadchip kit feature 850,000 cytosine-phosphate-guanine cpg site enhancer region gene body promoter cpg island dna methylation array imaged using standard illumina procedure illumina iscan scanner illumina inc. san diego usa quality control ewas performed quality control dna methylation data extracted raw intensity data idat including signal intensity probe chip million probe minimize unintended variation within sample implemented quantile normalization considers methylated unmethylated signal intensity separately excluded probe detection p-value 0.05 considered low-quality signal sample detection p-value calculated using method compare total dna signal methylated unmethylated site background signal level estimated using negative control site assuming normal distribution cpg site failed one sample filtered based detection p-value removed probe chromosome addition probe affected single nucleotide polymorphism snp without specification certain minor allele frequency addition non-specific binding probe mapped multiple location genome filtered annotation performed illumina infinium methylationepic beadchip epic chip microarray platform designed dna methylation across 860,000 cpg site human genome finally 784,864 1,051,815 probe passed quality control included ewas supplementary fig cpg site associated ckd progression identified using linear regression model implemented limma package empirical bayesian framework methylation level cpg probe represented m-values beta-value commonly used measure dna methylation range representing proportion methylation given cpg site conversely m-value logit-transformed beta-value log2 ratio intensity methylated versus unmethylated probe calculated log max methyl ,0+\alpha max methyl 0\right +\alpha m-value advantage symmetrical around zero often used statistical analysis allows accurate measurement differential methylation group m-value range value close zero indicating low methylation increasingly negative positive value indicating higher level hypomethylation hypermethylation respectively since difference various cell type whole blood progression non-progression lead false differentiated methylation region effect cell proportion result ewas considered therefore addition original model without adjustment blood cell proportion referred model also adjusted blood cell proportion including lymphocyte cell monocyte cell neutrophil remove false cpg site difference cell proportion based houseman method referred model furthermore adjusted body mass index bmi smoking status yes/no covariates referred model summary statistic provided supplementary table result study methylation difference primary outcome diabetic ckd progression versus non-progression following implementation epigenome-wide significance threshold 0.05 using false discovery rate fdr number cpg site reduced total 784,864 9,809 8,900 8,690 model model model respectively supplementary fig supplementary fig subsequently cpg site without annotation gene symbol removed cpg site model model model respectively selected cpg site located promoter region promoter defined region located upstream transcriptional start site tss 5′utr 1st exon cpg site model model model respectively addition cpg site located shelf shore region cpg island cgi selected cpg site model model model respectively furthermore cpg site restricted fdr threshold fdr 0.005 selected perform pyrosequencing in-silico functional analysis cpg site model model model respectively used top five percentile m-value| threshold distribution m-value| exclude false positive cpg site since m-value| left skewed distribution determined top five percentile value based non-parametric bootstrapping resampling method alpha 0.05 number resampling supplementary fig top five percentile value quantile estimated quantile 0.2954 0.2915 0.3002 based resampling distribution addition top five percentile value ewas adjustment blood cell proportion estimated quantile 0.3007 0.2958 0.3045 supplementary fig furthermore top five percentile value ewas adjustment blood cell proportion also bmi smoking status estimated quantile 0.0382 0.0371 0.0393 supplementary fig therefore selected highly significant cpg site │∆m-value│ 0.30 model cpg site model model │∆m-value│ 0.038 model cpg site model respectively quality control genome-wide analysis conducted using minfi package bioconductor platform pyrosequencing replication analysis candidate cpg site used pyrosequencing analysis selected result ewas adjustment blood cell proportion supplementary fig supplementary fig pyrosequencing primer designed using pyromark assay design 2.0 software qiagen following three condition maximum amplicon length primer set score primer attached cpg site excluded supplementary fig ultimately cpg site cg11513352 cg10297223 cg22773662 cg03503634 cg04089320 cg20746451 cg14279121 cg15280188 cg11508872 cg21285133 cg02990553 within gene doc2a agtr1 angiotensin receptor type mief1 traf6 emb smarcad1 osbpl9 aspscr1 rab14 anp32e krt28 keratin respectively available undergo pyrosequencing analysis three condition primer sequence used study listed supplementary table assay bisulfite-converted dna amplified using pcr using instruction provided manufacture pyromark pcr kit qiagen pcr product bound magnetic streptavidin bead quality control pyrosequencing data performed using pyromark q48 software sample passed quality control process sequencing performed pyromark q48 autoprep system using pyromark q48 advanced cpg reagent qiagen according manufacturer instruction percentage dna methylation specific cpg site estimated using pyromark q48 autoprep 2.4.2 software qiagen exported statistical environment subsequently linear regression performed cpg site covered assay well average methylation value across region performed linear regression analysis average methylation level methylated cytosine dependent variable progression/non-progression independent variable select cpg site show differential methylation level two group progression/non-progression beta estimation regression used calculate difference methylation level two group supplementary table phenome-wide association study performed phewas cg10297223 cg02990553 cpg site based variable phenotype know-ckd cohort based total 1,028 variable know-ckd cohort excluded variable missing rate remaining variable including phewas continuous categorical variable association cpg site phenotype estimated using linear logistic regression model according continuous categorical phenotype respectively statistical significance threshold phewas also set fdr 0.05 using benjamini–hochberg method silico functional analysis performed functional annotation analysis analysis disease-gene network dgn reactome pathway protein–protein interaction ppi network identify biological mechanism cpg site dng used identify cross-phenotypes associated selected gene cpg site using disgenet also used database annotate gene set biological pathway ppi network constructed using search tool retrieval interacting gene string http confidence score 0.99 identify functional interaction protein statistical significance determined false discovery rate fdr -corrected p-value 0.05 furthermore identified expression quantitative trait methylation eqtm based human whole-blood epigenome-wide association study human kidney eqtm susztak lab available http network illustration functional analysis constructed using cytoscape software version 3.9.1 via rcy3 dna methyltransferase dnmt inhibitor treatment hek cell cultured dulbecco modified eagle medium thermo fisher scientific waltham usa supplemented fetal bovine serum fbs thermo fisher scientific u/ml penicillin thermo fisher scientific μg/ml streptomycin thermo fisher scientific atmosphere containing humidified air demethylate methylated cpg site hek cell treated increasing concentration 5-aza-2′-deoxycytidine sigma-aldrich st. louis usa replaced daily inhibition methylation examined pyrosequencing analysis change agtr1 expression measured reverse-transcription quantitative polymerase chain reaction rt-qpcr rna preparation reverse-transcription quantitative polymerase chain reaction rt-qpcr total rna extracted hek cell using rneasy mini kit qiagen valencia usa according manufacturer protocol one microgram total rna converted cdna using superscript reverse transcriptase invitrogen carlsbad usa oligo- 12–18 primer thermo fisher scientific according manufacturer instruction qrt-pcr performed reaction mixture containing cdna sybr premix taq takara bio otsu japan 0.4 rox reference dye 50× takara bio primer gene following primer sequence used study agtr1 forward 5′-gccctttggcaattacctatgt-3′ agtr1 reverse 5′-cgtgagtagaaacacactagcgt-3′ gapdh forward 5′-aatcccatcaccatcttcca-3′ gapdh reverse 5′-tggactccacgacgt actca-3′ reaction run fast real-time pcr system applied biosystems foster city usa followed cycle single cycle generate dissociation curve pcr reaction performed triplicate specificity reaction determined melting curve analysis comparative quantification target gene performed based cycle threshold normalized gapdh using δδct method result general characteristic study population table show clinical demographic characteristic diabetic participant ckd progression versus non-progression based know-ckd cohort study mean age 59.1 year men accounted participant participant hypertension 98.3 urine albumin urine protein uacr upcr 24-h urine protein 24-h urine phosphorus level higher progression group non-progression group table table general characteristic diabetic chronic kidney disease based korean cohort study outcome patient chronic kidney disease know-ckd cohort study full size table furthermore supplementary table show general characteristic know-ckd cohort biopsy snuh human biobank pyrosequencing analysis diastolic blood pressure urine albumin urine protein uacr upcr 24-h urine protein level higher progression group non-progression group among participant however limited number variable investigated among participant differentially methylated cpg site result adjustment blood cell proportion cpg site remained based fdr 0.005 m-value|≥ 0.3 threshold fig supplementary fig according result adjustment blood cell proportion threshold cpg site identified supplementary fig based result adjustment blood cell proportion bmi smoking status cpg site remaining based fdr 0.005 m-value|≥ 0.038 threshold supplementary fig cpg site cpg site cg20746451 cg01490296 cg10297223 cg02990553 cg06205244 cg21285133 cg04089320 cg22773662 cg03503634 cg15280188 cg21285782 cg14279121 cg11508872 cg26296769 identical cpg site seven cpg site cg20746451 cg01490296 cg10297223 cg02990553 cg06205244 cg21285133 cg04089320 identical original cpg site respectively table supplementary fig figure visualization methylated probe manhattan quantile–quantile plot epigenome-wide association study ckd progression volcano plot showing differentially methylated cpg site x-axis present m-value difference signal intensity primary outcome probe y-axis represents -log10 p-value significant cpg site fdr 0.05 m-value| 0.30 highlighted red green cpg site highlighted red blue hypermethylated hypomethylated compared non-progression respectively fdr false discovery rate full size image table candidate cpg site primer design external validation based pyrosequencing analysis full size table result pyrosequencing provided information proportion methylated cytosine dna sample well information average level methylation individual cpg site candidate cpg site available pyrosequencing primer design six gene doc2a mief1 emb smarcad1 aspscr1 anp32e could considered validated due inconsistent direction effect size discovery result supplementary table remaining five gene three gene traf6 osbpl9 rab14 difficult validate due small effect size despite consistent direction effect size discovery result ewas cg10297223 agtr1 ewas ∆m-value 0.365 fdr 3.18e−03 pyrosequencing beta 0.788 0.397 p-value 4.90e−02 considered potentially validated whereas cg02990553 krt28 ewas ∆m-value 0.350 fdr 2.84e−04 pyrosequencing beta 0.459 0.912 p-value 6.10e−01 demonstrated consistent direction effect size without sufficient evidence statistical validation pyrosequencing analysis respectively table fig addition cg10297223 cg02990553 associated seven phenotype 24-h urine protein 24-h urine phosphorus urine albumin urine protein upcr uacr egfr slope based phewas table figure dna methylation analysis epigenome-wide association study discovery pyrosequencing validation progression chronic kidney disease ckd diabetic ckd patient beeswarm box plot show dna methylation value two cpg site m-values beta-values epigenome-wide association study based epic beadchip cg02990553 agtr1 cg10297223 krt28 percentage differentially methylated cpg site using pyrosequencing generated cg02990553 agtr1 cg10297223 krt28 full size image table phenome-wide association study based m-values cg10297223 agtr1 cg02990553 krt28 full size table silico functional analysis based functional analysis dgn agtr1 stox1 associated elevated systolic fdr 3.22e−02 diastolic fdr 3.22e−02 fig addition agtr1 nt5c2 associated pre-hypertension fdr 3.53e−02 agtr1 kcnc4 associated adverse event associated cardiac arrhythmia fdr 3.59e−02 agtr1 also associated traf6 based ppi network krt28 involved biological pathway developmental biology keratinization formation cornified envelope fdr 3.39e−39 based pathway fig supplementary table addition four cpg site g15280188 cg14279121 cg04089320 cg11513352 among total top cpg site identified eqtm supplementary table figure functional analysis cg10297223 agtr1 cg02990553 krt28 associated diabetic ckd blue orange red green node indicate cpg sty gene symbol disease-gene network reactome pathway respectively node molecular structure indicate ppi network ckd chronic kidney disease ppi protein–protein interaction full size image agtr1 expression regulated epigenetic dna methylation determine whether expression agtr1 mrna epigenetically modulated treated hek cell dna methyltransferase inhibitor 5-aza-2′-deoxycytidine expression agtr1 mrna quantified rt-qpcr methylation status cpg site cg10297223 within agtr1 determined pyrosequencing analysis treatment 5-aza-2′-deoxycytidine expression agtr1 mrna significantly restored 1.67-fold dose-dependent manner occurred concurrently decreased methylation status agtr1 promoter cpg site fig result indicate agtr1 expression regulated dna methylation-dependent mechanism figure modulation agtr1 mrna expression following demethylation hek cell hek cell treated various concentration 5-aza-2′-deoxycytidine treatment demethylation agtr1 promoter cpg site cg10297223 confirmed pyrosequencing analysis expression agtr1 mrna measured rt-qpcr data presented mean three independent experiment statistical analysis performed using one-way anova dunnett multiple comparison post-test comparing significance untreated control 0.05 0.01 0.001 5-aza 5-aza-2′-deoxycytidine full size image discussion study ewas performed select cpg site differentially methylated progression diabetic ckd korean population external replication analysis performed using pyrosequencing focusing top-ranked candidate cpg site consequently cg10297223 agtr1 cg02990553 krt28 found significant cpg marker gene-level functional analysis performed confirm two cpg site share biological mechanism diabetic ckd progression based existing knowledge hypothesis agtr1 g-protein-coupled transmembrane receptor located end renin–angiotensin–aldosterone system raas cascade raas cascade major regulator systemic arterial blood pressure fluid electrolyte balance primarily function second stage embryo play essential role neonate maintenance peripheral vascular resistance renal blood flow addition interaction agtr1 angiotensin released mesangial cell demonstrated activate inflammatory cascade regulating protein kinase mitogen-activated protein kinase mapk pathway induce expression growth factor proliferative cytokine sustain generation nephrotoxic reactive oxygen resulting inflammation fibroblast formation collagen deposition angiotensin also activates signaling nf-κb pathway activated tnf-receptor-associated factor traf leading inflammation therefore suggested pathogenic mutation leading absence defect agtr1 induce fatal phenotype moreover chronic activation raas recognized critical factor ckd progression addition non-functioning raas cascade result kidney damage neonatal hypoxic condition study agtr1 -related ckd raas gwas level also reported systematic review meta-analysis chronic renal insufficiency cohort study based caucasian african american population association raas-related gene ckd reported agtr1 found significantly associated ckd however another gwa study african american population reported association agtr1 diabetic eskd nevertheless previous study reported association allele snp agtr1 ckd study gene activation gene expression methylation agtr1 especially korean population yet described krt28 encodes member type acidic keratin family belongs superfamily intermediate filament protein previous study reported cornified envelope keratinization associated krt28 also associated ckd component cornified envelope considerably reduced participant ckd compared control group previous study reported treatment emollient reduce thickness density scale noticeably improve quality life ckd moreover acquired perforating dermatosis apd caused chronic friction leading epithelial proliferation abnormal keratinization decreased blood supply due microangiopathy often associated underlying systemic disease diabetes mellitus ckd apd often occurs starting dialysis ckd kidney damage known affect wound healing research data rat also showed exacerbating effect ckd wound healing mediated disruption keratinization delayed granulation addition veiled chronic inflammatory condition low rate angiogenesis cell proliferation also contribute poor wound healing although several krt series gene related keratinization reported previous study krt28 particularly epigenetic marker korean population implicated first time study previous study based similar hypothesis reported population korean previous study reported enhancement renal regulatory region correlation gene expression change including epidermal growth factor related kidney damage impaired function using methylation probe another study reported similar correlation result individual receiving kidney transplant dialysis demonstrating ability analyze transplant recipient alongside individual receiving dialysis improve performance future ewas eskd study several limitation need acknowledged first although selected candidate cpg site performing external replication analysis using pyrosequencing epigenome-wide replication analysis could performed owing lack korean asian-based ckd cohort epigenomic database nevertheless since know-ckd cohort form basis current study almost completed recruitment additional ckd participant phase started follow-up http able conduct epigenome-wide validation analysis future second dna sample used study derived peripheral blood sample limited information association whole blood dna methylation profile kidney tissue-specific dna methylation differentiation part due heterogeneity cell type within kidney however previous study suggested blood dna methylation analysis valuable reflect change dna methylation tissue associated phenotype nevertheless establishment biobank kidney biopsy needed improve tissue-specific dna methylation analysis kidney disease future although used threshold m-value| 0.3 0.0038 ewas with/without adjustment blood cell proportion adjustment blood cell proportion bmi smoking status respectively order exclude false positive cpg probe possibility cpg probe small difference considered candidate cpg site validation due high threshold m-value| possibility cg10297223 cg02990553 could validated pyrosequencing analysis study however although cg10297223 significant raw p-value p-value 0.05 cpg site statistical significance fdr bonferroni correction supplementary table future hope validate finding utilizing know-ckd phase cohort already mentioned include additional ckd participants—the recruitment participant almost completed since human kidney eqtm result gathered susztak lab sampled different ethnic group ethnicity cohort used study may association korean-specific epigenetics marker gene expression yet identified furthermore use 5-aza-2′-deoxycytidine result demethylation cpgs throughout genome cell making challenging apply treatment causal analysis effect therefore caution exercised interpreting result observed change may directly attributable targeted cpg site despite limitation study several strength first although epigenome-wide replication analysis could performed functional annotation analysis conducted silico elucidate biological mechanism cpg site identified study moreover based phewas cpg site associated diabetic ckd study confirmed appreciably associated different phenotype related ckd progression second although dna sample used study whole blood dna sample gene family reported gwas-level previous study also identified finding moreover study demonstrated epigenetic marker affect gene expression proteomic production central dogma gwas-level furthermore since cpg marker extracted clinically accessible peripheral blood sample used diagnostic marker future identified two epigenetic marker cg10297223 agtr1 cg02990553 krt28 show potential association diabetic ckd progression korean population based functional annotation phewas gene cpg site may offer insight activation genetic marker diabetic ckd suggesting cg10297223 cg02990553 could considered potential clinical biomarkers nevertheless study necessary validate association whole blood kidney tissue-specific dna methylation